The figures for 2025 showed pro forma revenue growth of 5%. TMV is planning for revenue growth of 0% to 3% in 2026. It emphasises that Q1 and Q2 are likely to be weak (the same quarters last year benefited from price increases in the SMB segment). Based on 2025 EPS (€0.75), TMV is currently trading at an unusually low P/E ratio of around 7 for the current year. The reasons for this are lost confidence, the underperformance of the acquired 1E to date and the structurally weak remote SMB business,...
Die vorläufigen 2025er-Zahlen brachten auf Pro-forma-Basis noch ein Umsatzwachstum von 5%. Für 2026 plant TMV mit 0% bis 3%igem Umsatzwachstum. Dabei wird betont, dass Q1 und Q2 schwach werden dürften (die Vorjahresquartale hatten von Preisanhebungen im SMB-Bereich profitiert). Auf Basis des 2025er EPS (€ 0,75) handelt TMV derzeit mit einem ungewöhnlich niedrigen KGV um 7 für das laufende Jahr. Gründe hierfür liegen in verlorenem Vertrauen, der bisherigen Unterperformance der zugekauften 1E und ...
Adyen: New Platforms partnership in APAC / Dutch Pension Reform (Wtp): 1/3 transitioned (c.25 funds), 2027 challenging / IBA: Sale of a P1 system to MacKay Memorial Hospital in New Taipei City, Taiwan / KPN: 4Q25 preview / Offshore Wind: North Sea offshore wind pact to develop 300GW by 2050 / Vår Energi: RRR 2P 185% offsets slight pressure on expected production volumes 4Q
We believe that Allfunds has been sold below the valuation warranted by its platform peers but, in the likely absence of a competing bid, we reduce our 12-month target price from €12.86 to the bid value of €8.80 given that we expect Deutsche Boerse's bid will succeed. Correspondingly, our recommendation is changed from Buy to HOLD.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.